Search
INCY;PFE:ESMO Abstracts: IDO inhibitor underwhelms, PFE/MRCG anti PD-L1 appears modest
ESMO Abstracts out...
With new Abstracts from the upcoming ESMO/ECC cancer conference just published we take a critical first look at the new data on novel IDO inhibitor immunotherapy from Incyte, and Pfizer/Merck KGaA's latest anti PD-L1 avelumab, to see how they stack up.
